First Savings Financial Group, Inc. Logo
First Savings Financial Group, Inc. Announces Quarterly Cash Dividend
February 28, 2024 17:22 ET | First Savings Financial Group, Inc.
JEFFERSONVILLE, Ind., Feb. 28, 2024 (GLOBE NEWSWIRE) -- First Savings Financial Group, Inc. (NASDAQ: FSFG) (the “Company”), the holding company for First Savings Bank (the “Bank”), announced that...
Portage Biotech.png
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
February 28, 2024 17:10 ET | Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
Cytek Logo - Color.jpg
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
February 28, 2024 17:05 ET | Cytek Biosciences, Inc.
FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
February 28, 2024 17:00 ET | atai Life Sciences
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
Picture1.png
Portillo’s Inc. Announces Offering of Class A Common Stock in “Synthetic Secondary” Transaction
February 28, 2024 16:45 ET | Portillo’s Inc.
CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portillo’s Inc. (“Portillo’s” or the “Company”) (Nasdaq: PTLO), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
February 28, 2024 16:45 ET | ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
CBAY Logo.jpg
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
February 28, 2024 16:45 ET | CymaBay Therapeutics, Inc.
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted seladelpar NDA for priority review, and seladelpar...
Milestone Pharmaceuticals Logo.png
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
February 28, 2024 16:37 ET | Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and...
Supernus Pharmaceuticals, Inc.
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024 16:30 ET | Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
aim.jpg
Aimfinity Investment Corp. I Announces Eighth Extension of the Deadline for an Initial Business Combination to March 28, 2024
February 28, 2024 16:30 ET | Aimfinity Investment Corp. I
Wilmington, Delaware, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman...